Reagents of clinical utility in the evaluation of mature T- and NK-cell lymphoid neoplasms
| Reagent . | Normal distribution . | Clinical utility in mature T- and NK-cell lymphoid neoplasms . | Comments . |
|---|---|---|---|
| CD2 | T cells and NK cells. | Indicator of T- or NK-cell lineage. | May be aberrantly expressed in AML. |
| CD3, surface | Acquired during maturation of T cells. | Indicator of T-cell lineage. May be aberrantly lost or decreased in intensity. | — |
| CD4 | T-cell subset and monocytes/histiocytes. | Useful in classification of mature T-cell lymphoid neoplasms. | NOT indicator of clonality. Also may be positive in AML and HDN. |
| CD5 | T cells and minor B-cell subset. | Indicator of T-cell lineage. May be aberrantly lost or decreased in intensity. | May be aberrantly expressed on B cells. |
| CD7 | T cells and NK cells. | Indicator of T-cell lineage. May be aberrantly lost or decreased in intensity. | Some normal and reactive CD7− cells. May be aberrantly expressed in AML. |
| CD8 | T-cell subset and some NK cells. | Useful in classification of mature T-cell lymphoid neoplasms. | NOT indicator of clonality |
| CD45 | All B cells (weaker intensity on precursors and plasma cells), all T cells (weaker intensity on precursors). | Useful in distinguishing mature lymphoid neoplasms (bright intensity) from ALL and PCN (weak intensity to negative). | — |
| CD56 | NK cells and NK-like T cells. | Indicator of NK differentiation. | Aberrant expression in AML, PCN. Positive HDN. Small subset of regenerating myeloid cells demonstrates weak expression. |
| CD1a* | Immature T cells. | ALL. | Also positive on Langerhans cells. |
| CD3, cytoplasmic* | All T cells including lymphoblasts. | Indicator of T- or NK cell lineage. NK cells contain cCD3 epsilon. | — |
| CD10* | Immature T cells and B cells, subset of mature T cells and B cells, and neutrophils. | Frequently present in ALL. Found on some mature T-cell neoplasms, in particular AITCL. | Minor subset of normal T cells. |
| CD16* | NK cells, NK-like T cells, and maturing neutrophilic cells. | Indicator of NK differentiation. | Antibodies with differing specificity for lymphoid cells and neutrophilic cells.. |
| CD25* | Activated T cells. | Uniform strong positivity in ATLL. More variable expression in other subtypes. Assessment for anti-CD25 therapy, eg, Ontak. | — |
| CD26* | Immature T cells, NK cells, and activated T cells. Most CD4+ T cells also CD26+. | CTCL/Sézary syndrome often CD26 negative (> 30% CD4+ cells, CD26−). | Not specific for Sézary/CTCL. |
| CD30* | Activated T and B cells, and monocytes. | Strong uniform staining in ALCL. More variable staining in other mature T- and NK-cell neoplasms. Positive in Hodgkin lymphoma. | — |
| CD45RA* | B- and T-cell subsets, including mostly naive T cells. | May help to identify restricted population. | — |
| CD45RO* | B- and T-cell subsets, including mostly memory T cells. | May help to identify restricted population. | — |
| CD57* | NK cells, NK-like T cells. | Indicator of NK-differentiation. | — |
| TCR α/β* | Mature T cells in association with sCD3. | Classification mature T-cell lymphoid neoplasms. | — |
| TCR γ/δ* | Mature T cells in association with sCD3. | Classification mature T-cell lymphoid neoplasms. May help to identify restricted population. | — |
| TIA-1* | Cytotoxic T cells. | Classification mature T-cell lymphoid neoplasms. | — |
| T-β* chain isoforms | T cells. | Restricted expression associated with clonality. | — |
| Reagent . | Normal distribution . | Clinical utility in mature T- and NK-cell lymphoid neoplasms . | Comments . |
|---|---|---|---|
| CD2 | T cells and NK cells. | Indicator of T- or NK-cell lineage. | May be aberrantly expressed in AML. |
| CD3, surface | Acquired during maturation of T cells. | Indicator of T-cell lineage. May be aberrantly lost or decreased in intensity. | — |
| CD4 | T-cell subset and monocytes/histiocytes. | Useful in classification of mature T-cell lymphoid neoplasms. | NOT indicator of clonality. Also may be positive in AML and HDN. |
| CD5 | T cells and minor B-cell subset. | Indicator of T-cell lineage. May be aberrantly lost or decreased in intensity. | May be aberrantly expressed on B cells. |
| CD7 | T cells and NK cells. | Indicator of T-cell lineage. May be aberrantly lost or decreased in intensity. | Some normal and reactive CD7− cells. May be aberrantly expressed in AML. |
| CD8 | T-cell subset and some NK cells. | Useful in classification of mature T-cell lymphoid neoplasms. | NOT indicator of clonality |
| CD45 | All B cells (weaker intensity on precursors and plasma cells), all T cells (weaker intensity on precursors). | Useful in distinguishing mature lymphoid neoplasms (bright intensity) from ALL and PCN (weak intensity to negative). | — |
| CD56 | NK cells and NK-like T cells. | Indicator of NK differentiation. | Aberrant expression in AML, PCN. Positive HDN. Small subset of regenerating myeloid cells demonstrates weak expression. |
| CD1a* | Immature T cells. | ALL. | Also positive on Langerhans cells. |
| CD3, cytoplasmic* | All T cells including lymphoblasts. | Indicator of T- or NK cell lineage. NK cells contain cCD3 epsilon. | — |
| CD10* | Immature T cells and B cells, subset of mature T cells and B cells, and neutrophils. | Frequently present in ALL. Found on some mature T-cell neoplasms, in particular AITCL. | Minor subset of normal T cells. |
| CD16* | NK cells, NK-like T cells, and maturing neutrophilic cells. | Indicator of NK differentiation. | Antibodies with differing specificity for lymphoid cells and neutrophilic cells.. |
| CD25* | Activated T cells. | Uniform strong positivity in ATLL. More variable expression in other subtypes. Assessment for anti-CD25 therapy, eg, Ontak. | — |
| CD26* | Immature T cells, NK cells, and activated T cells. Most CD4+ T cells also CD26+. | CTCL/Sézary syndrome often CD26 negative (> 30% CD4+ cells, CD26−). | Not specific for Sézary/CTCL. |
| CD30* | Activated T and B cells, and monocytes. | Strong uniform staining in ALCL. More variable staining in other mature T- and NK-cell neoplasms. Positive in Hodgkin lymphoma. | — |
| CD45RA* | B- and T-cell subsets, including mostly naive T cells. | May help to identify restricted population. | — |
| CD45RO* | B- and T-cell subsets, including mostly memory T cells. | May help to identify restricted population. | — |
| CD57* | NK cells, NK-like T cells. | Indicator of NK-differentiation. | — |
| TCR α/β* | Mature T cells in association with sCD3. | Classification mature T-cell lymphoid neoplasms. | — |
| TCR γ/δ* | Mature T cells in association with sCD3. | Classification mature T-cell lymphoid neoplasms. May help to identify restricted population. | — |
| TIA-1* | Cytotoxic T cells. | Classification mature T-cell lymphoid neoplasms. | — |
| T-β* chain isoforms | T cells. | Restricted expression associated with clonality. | — |
Reagents included in this table were recommended in the consensus guidelines.
sCD3 indicates surface CD3.
These reagents may be considered for secondary evaluation, after other reagents listed have been used in the initial evaluation.